Advertisement

Current Allergy and Asthma Reports

, Volume 13, Issue 6, pp 587–595 | Cite as

Clinical Consequences of Targeting IL-17 and TH17 in Autoimmune and Allergic Disorders

  • Keven M. Robinson
  • Michelle L. Manni
  • Partha S. Biswas
  • John F. Alcorn
Immune Deficiency and Dysregulation (DP Huston, Section Editor)

Abstract

The TH17 lineage of T cells and its canonical cytokine IL-17 have been the focus of many recent studies in autoimmune, allergic, and infectious disease. In this review, we will briefly discuss the current knowledge about the role of these cells and IL-17 in a spectrum of disorders. It is clear that IL-17 plays pathogenic roles in certain conditions while the same pathway is critically important to immunity in others. Targeting of TH17 cells or IL-17 therapeutically may impart many benefits, but this approach is not without potentially serious implications regarding host defense. These issues will be discussed herein as we evaluate pharmacological approaches targeting this pathway that are just beginning to be fully tested in human disease.

Keywords

Inflammation Immunity Host defense Allergy Asthma Lung Arthritis Psoriasis Lupus Crohn’s disease Pneumonia Multiple sclerosis IL-17 Th17 Autoimmune 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

John F. Alcorn has received grant support from the National Institutes of Health, National Heart, Lung, & Blood Institute, Janssen Research and Development, and Gilead.

Keven M. Robinson declares that she has no conflict of interest.

Michelle L. Manni declares that she has no conflict of interest.

Partha S. Biswas declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Aujla SJ, Alcorn JF. T(H)17 cells in asthma and inflammation. Biochim Biophys Acta. 1810;2011:1066–79.Google Scholar
  2. 2.
    McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity. 2008;28:445–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008;28:29–39.PubMedCrossRefGoogle Scholar
  4. 4.
    Diveu C, McGeachy MJ, Boniface K, et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol. 2009;182:5748–56.PubMedCrossRefGoogle Scholar
  5. 5.
    Ramgolam VS, Sha Y, Jin J, et al. IFN-beta inhibits human Th17 cell differentiation. J Immunol. 2009;183:5418–27.PubMedCrossRefGoogle Scholar
  6. 6.
    Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448:484–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol. 2002;71:1–8.PubMedGoogle Scholar
  8. 8.
    Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14:155–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556–67.PubMedCrossRefGoogle Scholar
  10. 10.
    Kotenko SV, Izotova LS, Mirochnitchenko OV, et al. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem. 2001;276:2725–32.PubMedCrossRefGoogle Scholar
  11. 11.
    Wei CC, Ho TW, Liang WG, et al. Cloning and characterization of mouse IL-22 binding protein. Genes Immun. 2003;4:204–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004;50:650–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Koenders MI, Kolls JK, Oppers-Walgreen B, et al. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum. 2005;52:3239–47.PubMedCrossRefGoogle Scholar
  14. 14.
    Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122:201–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008;181:4733–41.PubMedGoogle Scholar
  16. 16.
    Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012;64:99–109.PubMedCrossRefGoogle Scholar
  19. 19.
    Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol. 2006;36:2868–74.PubMedCrossRefGoogle Scholar
  20. 20.
    Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8:500–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Nalbandian A, Crispin JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol. 2009;157:209–15.PubMedCrossRefGoogle Scholar
  22. 22.
    Crispin JC, Tsokos GC. IL-17 in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:943254.PubMedCrossRefGoogle Scholar
  23. 23.
    Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Dubinsky MC, Wang D, Picornell Y, et al. IL-23 receptor (IL-23R) gene protects against pediatric Crohn’s disease. Inflamm Bowel Dis. 2007;13:511–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Van Hauwermeiren F, Vandenbroucke RE, Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 2011;22:311–9.PubMedCrossRefGoogle Scholar
  27. 27.
    • Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52ra72. This is the first reported study of anti-IL-17 antibody therapy in RA.PubMedCrossRefGoogle Scholar
  28. 28.
    • Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62:929–39. This study discusses the clinical impact of an IL-17A targeted antibody in three relevant inflammatory disorders.PubMedCrossRefGoogle Scholar
  29. 29.
    •• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–9. This is the first study that showed that targeting of IL-17Ra is beneficial for the treatment of psoriasis.PubMedCrossRefGoogle Scholar
  30. 30.
    Baeten DL, Bek S, Wei JW, et al. Improvement in signs and symptoms of active Ankylosing Spondylitis following treatment with anti-interleukin (IL)-17A Monoclonal antibody Secukinumab are paralleled by reductions in acute phase markers and inflammatory markers S100A8 and A9 (Calgranulin A and B). Arthritis Rheumatism. 2012;64:S942–2.Google Scholar
  31. 31.
    Symons A, Budelsky AL, Towne JE. Are Th17 cells in the gut pathogenic or protective? Mucosal Immunol. 2012;5:4–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836–44.PubMedCrossRefGoogle Scholar
  33. 33.
    Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126:926–38.PubMedCrossRefGoogle Scholar
  34. 34.
    Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006;368:780–93.PubMedCrossRefGoogle Scholar
  35. 35.
    Hastie AT, Moore WC, Meyers DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol. 2010;125:1028–1036 e1013.PubMedCrossRefGoogle Scholar
  36. 36.
    Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma : evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest. 2001;119:1329–36.PubMedCrossRefGoogle Scholar
  37. 37.
    Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57:875–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Louis R, Lau LC, Bron AO, et al. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000;161:9–16.PubMedCrossRefGoogle Scholar
  39. 39.
    Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol. 1995;154:4719–25.PubMedGoogle Scholar
  40. 40.
    Schleimer RP, Freeland HS, Peters SP, et al. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. J Pharmacol Exp Ther. 1989;250:598–605.PubMedGoogle Scholar
  41. 41.
    Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549–58.PubMedCrossRefGoogle Scholar
  42. 42.
    Wakashin H, Hirose K, Maezawa Y, et al. IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med. 2008;178:1023–32.PubMedCrossRefGoogle Scholar
  43. 43.
    McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008;181:4089–97.PubMedGoogle Scholar
  44. 44.
    Agache I, Ciobanu C, Agache C, et al. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med. 2010;104:1131–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Bullens DM, Truyen E, Coteur L, et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res. 2006;7:135.PubMedCrossRefGoogle Scholar
  46. 46.
    Hashimoto T, Akiyama K, Kobayashi N, et al. Comparison of IL-17 production by helper T cells among atopic and nonatopic asthmatics and control subjects. Int Arch Allergy Immunol. 2005;137 Suppl 1:51–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Molet S, Hamid Q, Davoine F, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol. 2001;108:430–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Barczyk A, Pierzchala W, Sozanska E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med. 2003;97:726–33.PubMedCrossRefGoogle Scholar
  49. 49.
    Hellings PW, Kasran A, Liu Z, et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol. 2003;28:42–50.PubMedCrossRefGoogle Scholar
  50. 50.
    • Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One. 2011;6:e17160. This study identifies the protective allele IL-23R R381Q with significantly reduced IL-17A production and STAT3 phosphorylation, and illustrates a critical role for the IL-23/IL-23R signaling in generating pathogenic T H 17 responses.PubMedCrossRefGoogle Scholar
  51. 51.
    • Bossley CJ, Fleming L, Gupta A, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol. 2012;129:974–982 e913. This study shows that eosinophilia and airway remodeling is not associated with an elevation in T H 2 cytokines in pediatric patients with severe asthma.PubMedCrossRefGoogle Scholar
  52. 52.
    Leung DY, Spahn JD, Szefler SJ. Steroid-unresponsive asthma. Semin Respir Crit Care Med. 2002;23:387–98.PubMedCrossRefGoogle Scholar
  53. 53.
    Leung DY, Martin RJ, Szefler SJ, et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med. 1995;181:33–40.PubMedCrossRefGoogle Scholar
  54. 54.
    Naseer T, Minshall EM, Leung DY, et al. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med. 1997;155:845–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8:639–46.PubMedCrossRefGoogle Scholar
  56. 56.
    Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967–74.PubMedCrossRefGoogle Scholar
  57. 57.
    McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol. 2007;8:1390–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821–52.PubMedCrossRefGoogle Scholar
  59. 59.
    • Cosmi L, Maggi L, Santarlasci V, et al. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J Allergy Clin Immunol. 2010;125:222–230 e221-224. This study demonstrates a novel subset of human T cells that co-produce IL-4 and IL-17 (T H 2/T H 17 cells) in asthmatics.PubMedCrossRefGoogle Scholar
  60. 60.
    • Malmhall C, Bossios A, Radinger M, et al. Immunophenotyping of circulating T helper cells argues for multiple functions and plasticity of T cells in vivo in humans–possible role in asthma. PLoS One. 2012;7:e40012. This study examined expression of the transcription factors, T-bet, GATA-3, RORγt, and FOXP3 in T cells from asthmatics and found the majority expressed multiple transcription factors potentially indicating T cell plasticity in vivo.PubMedCrossRefGoogle Scholar
  61. 61.
    Alcorn JF, Crowe CR, Kolls JK. TH17 cells in asthma and COPD. Annu Rev Physiol. 2010;72:495–516.PubMedCrossRefGoogle Scholar
  62. 62.
    Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203:2271–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Ye P, Garvey PB, Zhang P, et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol. 2001;25:335–40.PubMedCrossRefGoogle Scholar
  64. 64.
    Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194:519–27.PubMedCrossRefGoogle Scholar
  65. 65.
    Happel KI, Dubin PJ, Zheng M, et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med. 2005;202:761–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Aujla SJ, Chan YR, Zheng M, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med. 2008;14:275–81.PubMedCrossRefGoogle Scholar
  67. 67.
    Ishigame H, Kakuta S, Nagai T, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity. 2009;30:108–19.PubMedCrossRefGoogle Scholar
  68. 68.
    Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008;14:282–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Yu JJ, Ruddy MJ, Conti HR, et al. The interleukin-17 receptor plays a gender-dependent role in host protection against Porphyromonas gingivalis-induced periodontal bone loss. Infect Immun. 2008;76:4206–13.PubMedCrossRefGoogle Scholar
  70. 70.
    Caruso R, Fina D, Paoluzi OA, et al. IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol. 2008;38:470–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Dubin PJ, Martz A, Eisenstatt JR, et al. Interleukin-23-mediated inflammation in Pseudomonas aeruginosa pulmonary infection. Infect Immun. 2012;80:398–409.PubMedCrossRefGoogle Scholar
  72. 72.
    Fedele G, Nasso M, Spensieri F, et al. Lipopolysaccharides from Bordetella pertussis and Bordetella parapertussis differently modulate human dendritic cell functions resulting in divergent prevalence of Th17-polarized responses. J Immunol. 2008;181:208–16.PubMedGoogle Scholar
  73. 73.
    Liu J, Feng Y, Yang K, et al. Early production of IL-17 protects against acute pulmonary Pseudomonas aeruginosa infection in mice. FEMS Immunol Med Microbiol. 2011;61:179–88.PubMedCrossRefGoogle Scholar
  74. 74.
    • Wu W, Huang J, Duan B, et al. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2012;186:420–7. Pseudomonas protein, PopB, is an antigen that stimulates a strong IL-17 response and serves as possible vaccine candidate for Pseudomonas aeruginosa.PubMedCrossRefGoogle Scholar
  75. 75.
    • Warfel JM, Merkel TJ. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol .2012. In a primate model of Bordatella pertussis, the authors observed increased expression of IL-17 in the mucosa of infected animals and two years later found circulating B. pertussis-specific T H 17 cells.Google Scholar
  76. 76.
    • Kudva A, Scheller EV, Robinson KM, et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol. 2011;186:1666–74. This study demonstrates viral suppression of subsequent T H 17 immunity against extracellular bacteria for the first time.PubMedCrossRefGoogle Scholar
  77. 77.
    Cheng P, Liu T, Zhou WY, et al. Role of gamma-delta T cells in host response against Staphylococcus aureus-induced pneumonia. BMC Immunol. 2012;13:38.PubMedCrossRefGoogle Scholar
  78. 78.
    Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Investig. 2009;119:1899–909.PubMedGoogle Scholar
  79. 79.
    Lu YJ, Gross J, Bogaert D, et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 2008;4:e1000159.PubMedCrossRefGoogle Scholar
  80. 80.
    Wu Q, Martin RJ, Rino JG, et al. IL-23-dependent IL-17 production is essential in neutrophil recruitment and activity in mouse lung defense against respiratory Mycoplasma pneumoniae infection. Microbes Infect/Inst Pasteur. 2007;9:78–86.CrossRefGoogle Scholar
  81. 81.
    Zhou X, Chen Q, Moore J, et al. Critical role of the interleukin-17/interleukin-17 receptor axis in regulating host susceptibility to respiratory infection with Chlamydia species. Infect Immun. 2009;77:5059–70.PubMedCrossRefGoogle Scholar
  82. 82.
    Godinez I, Raffatellu M, Chu H, et al. Interleukin-23 orchestrates mucosal responses to Salmonella enterica serotype Typhimurium in the intestine. Infect Immun. 2009;77:387–98.PubMedCrossRefGoogle Scholar
  83. 83.
    Raffatellu M, Santos RL, Verhoeven DE, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. 2008;14:421–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Khader SA, Pearl JE, Sakamoto K, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol. 2005;175:788–95.PubMedGoogle Scholar
  85. 85.
    Umemura M, Yahagi A, Hamada S, et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol. 2007;178:3786–96.PubMedGoogle Scholar
  86. 86.
    Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol. 2007;8:369–77.PubMedCrossRefGoogle Scholar
  87. 87.
    Woolard MD, Hensley LL, Kawula TH, et al. Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect Immun. 2008;76:2651–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Lin Y, Ritchea S, Logar A, et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity. 2009;31:799–810.PubMedCrossRefGoogle Scholar
  89. 89.
    • Xu S, Han Y, Xu X, et al. IL-17A-producing gammadeltaT cells promote CTL responses against Listeria monocytogenes infection by enhancing dendritic cell cross-presentation. J Immunol. 2010;185:5879–87. This study demonstrates the requirement for γδT cell-derived IL-17 in the primary CD8 + T cell response to Listeria monocytogenes.PubMedCrossRefGoogle Scholar
  90. 90.
    Rudner XL, Happel KI, Young EA, et al. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect Immun. 2007;75:3055–61.PubMedCrossRefGoogle Scholar
  91. 91.
    Werner JL, Metz AE, Horn D, et al. Requisite role for the dectin-1 beta-glucan receptor in pulmonary defense against Aspergillus fumigatus. J Immunol. 2009;182:4938–46.PubMedCrossRefGoogle Scholar
  92. 92.
    Zelante T, Bozza S, De Luca A, et al. Th17 cells in the setting of Aspergillus infection and pathology. Med Mycol: official publication of the International Society for Human and Animal Mycology. 2009;47 Suppl 1:S162–169.CrossRefGoogle Scholar
  93. 93.
    Conti HR, Shen F, Nayyar N, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009;206:299–311.PubMedCrossRefGoogle Scholar
  94. 94.
    • Gladiator A, Wangler N, Trautwein-Weidner K, et al. Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. J Immunol. 2013;190:521–5. This study identified innate lymphoid cells as a source of IL-17 during oral fungal infection.PubMedCrossRefGoogle Scholar
  95. 95.
    Wuthrich M, Gern B, Hung CY, et al. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J Clin Investig. 2011;121:554–68.PubMedCrossRefGoogle Scholar
  96. 96.
    Crowe CR, Chen K, Pociask DA, et al. Critical role of IL-17RA in immunopathology of influenza infection. J Immunol. 2009;183:5301–10.PubMedCrossRefGoogle Scholar
  97. 97.
    Wang X, Chan CC, Yang M, et al. A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection. Cell Mol Immunol. 2011;8:462–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Wiehler S, Proud D. Interleukin-17A modulates human airway epithelial responses to human rhinovirus infection. Am J Physiol Lung Cell Mol Physiol. 2007;293:L505–515.PubMedCrossRefGoogle Scholar
  99. 99.
    Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J Virol. 2012;86:12304–12.PubMedCrossRefGoogle Scholar
  100. 100.
    Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther. 2012;14:217.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Keven M. Robinson
    • 1
    • 2
  • Michelle L. Manni
    • 1
  • Partha S. Biswas
    • 2
  • John F. Alcorn
    • 1
    • 3
  1. 1.Department of PediatricsChildren’s Hospital of Pittsburgh of UPMCPittsburghUSA
  2. 2.Department of MedicineUniversity of Pittsburgh Medical CenterPittsburghUSA
  3. 3.Division of Pulmonary Medicine, Allergy, and ImmunologyChildren’s Hospital of Pittsburgh of UPMCPittsburghUSA

Personalised recommendations